insitro-Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab

Summary

SOUTH SAN FRANCISCO, Calif., October 06, 2026--insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitro and, critically, in vivo properties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained on multi-species preclinical data that Lilly generated over decades of research from h